Statement of Changes in Beneficial Ownership (4)
August 13 2020 - 4:12PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Schaeffer Orlov S Nicole |
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc
[
INSM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief People Strategy Officer |
(Last)
(First)
(Middle)
700 US HIGHWAY 202/206 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/15/2020 |
(Street)
BRIDGEWATER, NJ 08807
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock (1) | 5/15/2020 | | F | | 1126 | D | $25.46 | 35227 | D | |
Common Stock | 8/11/2020 | | M | | 3761 | A | $6.96 | 38988 | D | |
Common Stock | 8/11/2020 | | S | | 3761 | D | $30.07 (2) | 35227 | D | |
Common Stock | 8/12/2020 | | M | | 465 | A | $6.96 | 35692 | D | |
Common Stock | 8/12/2020 | | S | | 465 | D | $28.77 (3) | 35227 | D | |
Common Stock | 8/12/2020 | | M | | 4000 | A | $12.44 | 39227 | D | |
Common Stock | 8/12/2020 | | S | | 4000 | D | $28.80 (4) | 35227 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $6.96 | 8/11/2020 | | M | | | 3761 | (5) | 1/2/2023 | Common Stock | 3761 | $0 | 465 | D | |
Stock Option (right to buy) | $6.96 | 8/12/2020 | | M | | | 465 | (5) | 1/2/2023 | Common Stock | 465 | $0 | 0 | D | |
Stock Option (right to buy) | $12.44 | 8/12/2020 | | M | | | 4000 | (6) | 5/23/2023 | Common Stock | 4000 | $0 | 8500 | D | |
Explanation of Responses: |
(1) | Represents the withholding of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. This transaction was not reported previously due to a clerical error. |
(2) | This is the weighted average sales price representing 3,761 shares sold at prices ranging from $30.00 to $30.45 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. |
(3) | This is the weighted average sales price representing 465 shares sold at prices ranging from $28.75 to $28.79 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. |
(4) | This is the weighted average sales price representing 4,000 shares sold at prices ranging from $28.71 to $28.95 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. |
(5) | The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
(6) | On May 23, 2013, the reporting person was granted an option to purchase 25,000 shares of common stock. The option vests in two installments based upon the Issuer's satisfaction of two separate performance metrics. The first installment vested on February 26, 2015. The performance metric applicable to the second installment, the first written approval of a New Drug Application or Marketing Authorization Application from the Food and Drug Administration of European Medicines Agency, respectively, was met on September 28, 2018, resulting in the vesting of the second installment. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Schaeffer Orlov S Nicole 700 US HIGHWAY 202/206 BRIDGEWATER, NJ 08807 |
|
| Chief People Strategy Officer |
|
Signatures
|
/s/ S. Nicole Schaeffer, by Christine Pellizzari as Attorney-in-fact | | 8/13/2020 |
**Signature of Reporting Person | Date |
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024